SCHEMBL535593

SCHEMBL535593

CCCC(=O)Oc1ccc2ncccc2c1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.63
PDGFRB P09619 1/20 0.51
PDGFRA P16234 1/20 0.51
CA2 P00918 2/20 0.50
ALOX15 P16050 1/20 0.49
HTT P42858 1/20 0.49
PPARG P37231 2/20 0.48
PPARA Q07869 1/20 0.48
CYP3A4 P08684 1/20 0.47
ALOX5 P09917 1/20 0.47
RAB9A P51151 3/20 0.46
NPC1 O15118 2/20 0.46
PLK1 P53350 1/20 0.46
KMT2A Q03164 2/20 0.45
MAPT P10636 3/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
MEN1 O00255 1/20 0.44
POLB P06746 1/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
LMNA P02545 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28065837 0.89 ALDH1A1 (0.66) ALDH1A1PDGFRBPDGFRAALOX15HTT
SCHEMBL19924516 0.85 ALDH1A1 (0.69) ALDH1A1ALOX15HTTCYP3A4RAB9A
SCHEMBL27657434 0.83 ALDH1A1 (0.62) ALDH1A1ALOX15HTTPPARGPPARA
SCHEMBL19924517 0.82 ALDH1A1 (0.64) ALDH1A1ALOX15HTTPPARGPPARA
SCHEMBL3161907 0.81 ALDH1A1 (0.71) ALDH1A1PDGFRBPDGFRAALOX15HTT
SCHEMBL17448713 0.81 ALDH1A1 (0.53) ALDH1A1CA2ALOX15HTTPPARG
SCHEMBL29914018 0.81 PDGFRB (0.63) ALDH1A1PDGFRBPDGFRACA2PPARG
SCHEMBL5029679 0.81 PDGFRB (0.63) ALDH1A1PDGFRBPDGFRACA2PPARG
Hydrochloric Acid SCHEMBL27728003 0.80 ALDH1A1 (0.69) ALDH1A1PDGFRBPDGFRAALOX15HTT
SCHEMBL30039477 0.80 ALDH1A1 (0.54) ALDH1A1PDGFRBPDGFRAALOX15HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8507509-B2 Saturated and insaturated bi- or tricyclic aryloxyacetamine derivatives and their use as fungicides SYNGENTA CROP PROTECTION LLC (US) 2013-08-13 US disclosed
EP-2185518-B1 Aryloxyacetamide derivatives and their use as fungicides SYNGENTA PARTICIPATIONS AG (CH) 2012-02-08 EP disclosed
US-20100298356-A1 SATURATED AND INSATURATED BI- OR TRICYCLIC ARYLOXYACETAMINE DERIVATIVES AND THEIR USE AS FUNGICIDES SYNGENTA CROP PROTECTION, INC. (US) 2010-11-25 US disclosed
EP-2185518-A2 SATURATED AND INSATURATED BI- OR TRICYCLIC ARYLOXYACETAMIDE DERIVATIVES AND THEIR USE AS FUNGICIDES Syngenta Participations AG (CH) 2010-05-19 EP disclosed
WO-2009030467-A2 SATURATED AND INSATURATED BI- OR TRICYCLIC ARYLOXYACETAMIDE DERIVATIVES AND THEIR USE AS FUNGICIDES SYNGENTA PARTICIPATIONS AG, (CH) 2009-03-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298356-A1 SATURATED AND INSATURATED BI- OR TRICYCLIC ARYLOXYACETAMINE DERIVATIVES AND THEIR USE AS FUNGICIDES CYP1A2, CYP1B1, CYP1A1 ALDH1A1 109/4885PDGFRB 2764/4885PDGFRA 1856/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.